- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
South San Francisco Today
By the People, for the People
GSA Capital Partners LLP Buys Stake in Sutro Biopharma
The institutional investor purchased 174,843 shares of the biotech company's stock.
Published on Mar. 2, 2026
Got story updates? Submit your updates here. ›
GSA Capital Partners LLP, an institutional investor, purchased a new stake of 174,843 shares in Sutro Biopharma, Inc. (NASDAQ:STRO) during the third quarter, according to a recent SEC filing. The shares were valued at approximately $152,000, representing about 0.21% ownership of the biotech company.
Why it matters
This investment by GSA Capital Partners LLP in Sutro Biopharma reflects growing institutional interest in the biotech company, which is focused on developing novel biologic drug candidates in oncology and immunology. The purchase could signal confidence in Sutro's pipeline and future prospects.
The details
According to the SEC filing, GSA Capital Partners LLP acquired the 174,843 shares of Sutro Biopharma in the third quarter. This new stake represents about 0.21% ownership of the company. Sutro Biopharma is a clinical-stage biopharmaceutical company that leverages its proprietary cell-free protein synthesis platform to design and produce complex, multi-specific proteins for oncology and immunology applications.
- GSA Capital Partners LLP purchased the 174,843 shares of Sutro Biopharma in the third quarter.
The players
GSA Capital Partners LLP
An institutional investor that purchased a new stake in Sutro Biopharma, Inc.
Sutro Biopharma, Inc.
A clinical-stage biopharmaceutical company focused on developing novel biologic drug candidates in oncology and immunology.
The takeaway
This investment by GSA Capital Partners LLP underscores the growing institutional interest in Sutro Biopharma and its potential as a biotech company developing innovative therapies in oncology and immunology. The purchase could signal confidence in Sutro's pipeline and future prospects.
